News from medivir A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

02 Feb, 2017, 14:58 GMT Resolutions at the Extraordinary General Meeting in Medivir on 2 February 2017

Voluntary redemption programme The Extraordinary General Meeting in Medivir Aktiebolag (publ) on 2 February 2017 resolved, in accordance with the...


01 Feb, 2017, 07:48 GMT MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review of Safety Data Enables Trial Continuation Without any Modifications

edivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) held its fourth and final scheduled meeting...


10 Jan, 2017, 08:07 GMT Notice of Extraordinary General Meeting of Medivir AB (publ)

The shareholders in Medivir AB are hereby summoned to the Extraordinary General Meeting on Thursday 2 February 2017 at 2.00 p.m. at Konferenscentret...


29 Dec, 2016, 15:52 GMT Medivir Completes Previously Announced Oncology Programs Acquisition

Medivir AB (Nasdaq Stockholm: MVIR) today announces that the acquisitions of the two clinical stage oncology programs from TetraLogic Pharmaceuticals ...


15 Dec, 2016, 12:16 GMT Medivir Completes the Divestment of BioPhausia - a Transfer of Approx. SEK 870m to the Shareholders Through a Share Redemption Offer will be Proposed

Medivir AB (Nasdaq Stockholm: MVIR) announces today that the divestment of BioPhausia AB to Karo Pharma AB has been completed. The Board of Directors ...


14 Dec, 2016, 13:49 GMT Medivir's fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323, enters non-clinical development

Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-323 has been selected as a candidate drug (CD) from its fusion inhibitor project for the ...


20 Sep, 2012, 07:30 BST A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly

Medivir AB (OMX: MVIR), announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon...


21 Aug, 2012, 08:01 BST Clinical Phase Ia Trial on MIV-711 Complete and Phase Ib Trial Commences

Medivir AB (OMX: MVIR), the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is...


29 Jun, 2012, 07:30 BST Medivir Announces an Interferon-Free Phase II Combination Trial With TMC435 and daclatasvir to Commence Shortly

The phase II interferon-free combination study with TMC435 and daclatasvir will evaluate treatment-naïve or previous null responder patients with HCV ...


18 Apr, 2012, 13:54 BST Medivir Announces TMC435 in an Expanded Clinical Collaboration

Expanded clinical study program evaluating a combination of TMC435 and daclatasvir (BMS-790052) TMC435 and BMS-986094 (formerly INX-189), two...


04 Apr, 2012, 16:16 BST Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the EASL Meeting

- Including an Oral Presentation of final analysis of the TMC435 phase IIb ASPIRE (C206) study that have been selected to be highlighted during the...


13 Mar, 2012, 07:30 GMT Medivir Announces New Studies in Phase III Program for TMC435

Study in previous non-responder Hepatitis C genotype-1 infected patients Study in Hepatitis C genotype-4 infected patients MedivirAB (OMX: MVIR) a...


08 Feb, 2012, 07:30 GMT Medivir's Partner GSK Initiates OTC Launch of Xerclear® in Europe Under Trade Names Zoviduo and Zovirax Duo

Medivir AB (OMX: MVIR), the research-based specialty pharmaceutical company focused on infectious diseases, announces that its unique cold sore...


02 Dec, 2011, 12:30 GMT Medivir - TMC435 Will Be Evaluated in a Phase II Combination Study With daclatasvir (BMS 790052) for HCV Genotype-1 Patients

Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious...


02 Nov, 2011, 12:30 GMT Medivir Announces Final Results from TMC435 Phase IIb ASPIRE (C206) Study

TMC435-Based Therapy Significantly Improved Viral Cure Rates in Patients Who Failed Prior Treatment for Hepatitis C - ASPIRE: All TMC435 subgroups...


06 Jul, 2011, 12:00 BST TMC435 has Received Fast Track Designation From the FDAandTMC435 Will be Studied in Combination WithPharmasset's PSI-7977 for HCV genotype-1

Medivir AB (OMX: MVIR), is an emerging research-based specialty pharmaceutical company focused on infectious diseases. Medivir today announced that...


01 Apr, 2011, 06:00 BST Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner,...


01 Mar, 2011, 06:00 GMT Medivir's Cold Sore Treatment Xerese(TM) Now Launched in the United States

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the...


22 Feb, 2011, 06:00 GMT Medivir Announces Positive Phase 2b 48-week (SVR24) Interim Results of TMC435 in Treatment-Naive Patients Chronically Infected With Genotype-1 Hepatitis C Virus

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive ...


18 Feb, 2011, 10:48 GMT Medivir - The Phase 3 Program for TMC435 in Treatment-Naive Patients and Patients who Have Relapsed After Prior Interferon-Based Treatment has Now Started

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development...


14 Feb, 2011, 07:30 GMT Medivir Signs Research & Development Collaboration on Dengue Virus

Highlights of the Collaboration: - Collaboration with Janssen Pharmaceutica N.V. Focused on Dengue Virus - Both Parties to Contribute...


10 Feb, 2011, 12:00 GMT Medivir Announces Start of Phase 1a Trial of the Hepatitis C Polymerase Inhibitor TMC649128

Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces the start of a...